REG - Arix Bioscience Plc - Communications with Shareholders

Arix BioscienceAnnouncement

12/05/2022 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220512:nRSL9955Ka&default-theme=true

RNS Number : 9955K  Arix Bioscience Plc  12 May 2022

12 May 2022

 

ARIX BIOSCIENCE PLC (the "Company")

Electronic Communication with Shareholders

 

The Company is pleased to announce it has today posted a letter to all
Shareholders (the "Letter") requesting their individual consent to the use of
electronic means of communication and in that regard choose from three
options.

 

The Letter is also available on the Company's website:

https://arixbioscience.com/investor-relations/document-library
(https://arixbioscience.com/investor-relations/document-library)

 

 

Enquiries:

Email:     ir@arixbioscience.com (mailto:ir@arixbioscience.com)

LEI:          213800OVT3AHQCXNIX43

 

Registrar and Receiving Agent:  Equiniti Limited - 0371 384 2030 or +44 121
415 7047

Company Secretary: Kin Company Secretarial Limited - +44 20 8819 6486

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCURSSRUNUVAAR